89bio Inc (NAS:ETNB) Stock News, Headlines & Updates
89bio Inc Stock News from GuruFocus
- 1
Jul 12, 2024
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
Jun 14, 2024
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
May 22, 2024
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
Marketwired • 4:00pm
May 14, 2024
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
Marketwired • 7:00am
May 10, 2024
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired • 4:00pm
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
GuruFocus Research • 12:16pm
May 09, 2024
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Marketwired • 4:00pm
May 08, 2024
89bio to Participate in the BofA Securities 2024 Health Care Conference
Marketwired • 4:00pm
May 02, 2024
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH
Marketwired • 4:00pm
Apr 17, 2024
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Marketwired • 4:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news